The test provides oncologists with a new tool for monitoring blood level of 5-FU in cancer patients undergoing chemotherapy. This rapid test is said to be faster than currently available methods, enabling personalized dose management with the goal of minimizing toxicity and maximizing the therapeutic benefit of 5-FU treatment.
Olof Beck, laboratory director at the clinical pharmacology laboratory at Karolinska University Hospital, said: “We look forward to bringing this test to market to provide oncologists with an evidence-based tool to monitor individual patient dosing based upon their plasma 5-FU concentration level.
“As a result, physicians will be better able to manage their patients and make more confident decisions in colorectal cancer treatment.”